Nadler Financial Group Inc. Purchase 111 Shares of Johnson & Johnson (JNJ)

Nadler Financial Group Inc. Purchase 111 Shares of Johnson & Johnson (JNJ)

Nadler Financial Group Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,655 shares of the company’s stock after buying an additional 111 shares during the period. Johnson & Johnson makes up approximately 0.4% of Nadler Financial Group Inc.’s investment portfolio, making the stock its 24th largest position. Nadler Financial Group Inc.’s holdings in Johnson & Johnson were worth $1,203,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. ARGA Investment Management LP increased its position in shares of Johnson & Johnson by 10.0% in the third quarter. ARGA Investment Management LP now owns 2,200 shares of the company’s stock worth $260,000 after buying an additional 200 shares in the last quarter. Pegasus Partners Ltd. increased its position in shares of Johnson & Johnson by 10.7% in the third quarter. Pegasus Partners Ltd. now owns 25,535 shares of the company’s stock worth $3,016,000 after buying an additional 2,475 shares in the last quarter. Sandy Spring Bank increased its position in shares of Johnson & Johnson by 6.9% in the third quarter. Sandy Spring Bank now owns 113,896 shares of the company’s stock worth $13,525,000 after buying an additional 7,310 shares in the last quarter. Bank Pictet & Cie Asia Ltd. increased its position in shares of Johnson & Johnson by 53.2% in the third quarter. Bank Pictet & Cie Asia Ltd. now owns 47,500 shares of the company’s stock worth $5,611,000 after buying an additional 16,500 shares in the last quarter. Finally, Banque Pictet & Cie SA increased its position in shares of Johnson & Johnson by 8.7% in the third quarter. Banque Pictet & Cie SA now owns 581,616 shares of the company’s stock worth $68,706,000 after buying an additional 46,445 shares in the last quarter. 65.30% of the stock is owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (JNJ) opened at 128.78 on Friday. The firm has a market capitalization of $346.91 billion, a PE ratio of 21.65 and a beta of 0.74. The company has a 50-day moving average price of $124.85 and a 200 day moving average price of $119.87. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $129.00. Johnson & Johnson also was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 1,957 call options on the stock. This is an increase of 194% compared to the average volume of 665 call options.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.77 by $0.06. The firm had revenue of $17.77 billion for the quarter, compared to analysts’ expectations of $18.02 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. The business’s revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.68 EPS. Analysts expect that Johnson & Johnson will post $7.11 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 13th. Shareholders of record on Tuesday, May 30th will be issued a $0.84 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 2.61%. The ex-dividend date is Thursday, May 25th. Johnson & Johnson’s dividend payout ratio is currently 54.42%.

A number of brokerages recently commented on JNJ. Vetr downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price target for the company. in a report on Monday, May 15th. Cowen and Company restated a “buy” rating and set a $143.00 price objective (up previously from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. Morgan Stanley restated an “equal weight” rating and set a $135.00 price objective (up previously from $130.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. BTIG Research restated a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, May 21st. Finally, Stifel Nicolaus restated a “hold” rating and set a $128.00 price objective (up previously from $124.00) on shares of Johnson & Johnson in a research note on Thursday, May 18th. Eleven research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $130.90.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “JNJ”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Related posts

Leave a Comment